Work

Discovery of Quinazolinone Derivatives as Potent PARP1 Inhibitors

Year: 2026

Type: editorial

Abstract: Poly-(ADP-ribose) polymerase 1 (PARP1) is the most abundant and well-characterized member of PARP family and plays a significant role in DNA damage detection and repair. Cancer cells with homogeneous recombination deficiency (HRD) depend on PARP1 mediated DNA repair for survival, which makes PARP1 as a potential cancer treatment target. This patent highlights the synthesis and pharmaceutical composition of novel quinazolinone based PARP inhibitors for cancer treatment.

Source: ACS Medicinal Chemistry Letters

DOI: 10.1021/acsmedchemlett.5c00747

Authors: Xin Zhou, Steven H. Liang

Institutions: Emory University, Georgia Institute of Technology, The Wallace H. Coulter Department of Biomedical Engineering

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funder: National Institutes of Health

OpenAlex ID: W7123354762

Cites: 8

Cited by: 2

Related to: